Novel AI Tool Helps Patients to Find, Understand Clinical Trials

Article

Cancertrialsearch.com helped to match patients with gastrointestinal cancers to clinical trials using 7 different criteria, possibly paving the way for patients to find, understand, and enroll in oncology clinical trials.

According to an ongoing study presented at the 2020 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancer Symposium, a novel artificial intelligence (AI)-based search tool is now making it easier for patients to find and understand oncology clinical trials, while simultaneously offering more clarity on how patients can enroll in them.

Cancertrialsearch.com helped to match patients with gastrointestinal (GI) cancers to clinical trials using 7 different criteria, including trial sponsor, trial phase, tumor type, cancer stage, across solid tumors, by genetic mutations, and by previous treatment.

“Patients have limited access to an understanding of clinical trials and the online search tools that we have available – not only for patients, but even for providers – can be very hard to navigate,” study author Pashtoon Kasi, MD, MS, clinical assistant professor of internal medicine, hematology, oncology and blood and marrow transplantation at the University of Iowa Health Care, said during a virtual presentation at the symposium.

Improving understanding and access to clinical trials may result in more representative trial enrollment. Lack of diversity in clinical trials has been an issue that many researchers are facing, and can result in, “sometimes devastating medical consequences,” the researchers wrote.

After utilizing cancertrialsearch.com, participants were asked to complete a 20-minute survey evaluating both clinicaltrials.gov – which is commonly used for searching for trials – and the novel tool cancertrialsearch.com. Patients used a 5-point Likert scale to rate aspects of usability for each platform.

“We took GI clinical trials as an example of how this would be applicable to several other tumor types,” Kasi said. “The trial information is restructured based on key eligibility differentiators, [and] is patient-focused in terms of providing questionnaires that have been based on eligibility differentiators, which could be further personalized, and a value for institutions as well as patient advocacy groups.”

At baseline, the average rating for participants’ understanding of clinical trials was 3.1 (±1.2). Patient associations and the internet were their main sources of information about trials. Finding clinical trials was easier for patients using cancertrialsearch.com, compared to not using the tool (3.7±0.9 vs. 2.7±1.3, respectively).

Additionally, the researchers said that the tool improved patients’ understanding of information presented (3.8±1.1 vs. 2.6±1.3); and directionally provided more clarity on how to enroll in trials (4.2±0.8 vs. 3.7±1.4). Ultimately, these factors led to improved patient satisfaction (3.4±1.1 vs. 2.3±0.5).

Cancertrialsearch.com also could lead to better connection among principal investigators, patients and caregivers, and advocacy groups.

“In summary, with this cancertrialsearch.com tool, personalizing and simplifying client information can lead to better patient comprehension, as well as ease of access and navigation, leading to better patient satisfaction and an increased trial pool,” Kasi said. “This could mean broader and more diverse patient pool.”

Reference:

Kasi PM, Jordan E, Jahreiss L. Deploying an AI-based online search tool to increase patients’ access to and understanding of solid tumor GI clinical trials. J Clin Oncol. 2021;39 (suppl 3). Abstract #: 456.

Recent Videos
212Pb-DOTAMTATE showed “unexpectedly good” outcomes among those with gastroenteropancreatic neuroendocrine tumors, said Mary Maluccio, MD, MPH, FACS.
Trials at scale can be conducted in middle-income, low-middle-income, and even lower-income countries if you organize a trial ecosystem.
Immunotherapy-based combinations may elicit a synergistic effect that surpasses monotherapy outcomes among patients with muscle-invasive bladder cancer.
For example, you have a belt of certain diseases or genetic disorders that you come across, such as sickle cell disease or thalassemia, that are more prevalent in these areas.
Talent shortages in the manufacturing and administration of cellular therapies are problems that must be addressed at the level of each country.
Administering oral SERD-based regimens may enhance patients’ quality of life when undergoing treatment for ER-positive, HER2-negative breast cancer.
Point-of-care manufacturing, scalable manufacturing, and bringing the cost down [can help].
Gedatolisib-based triplet regimens may be effective among patients with prior endocrine resistance or rapid progression following frontline therapy.
Hosts Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, discuss presentations at ESMO 2025 that may impact bladder, kidney, and prostate cancer care.
Mandating additional immunotherapy infusions may help replenish T cells and enhance tumor penetration for solid tumors, including GI malignancies.
Related Content